Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Carlyle in talks to buy Baxter's kidney care unit, source says

Published 07/05/2024, 02:54 PM
Updated 07/05/2024, 03:25 PM
© Reuters. FILE PHOTO: The logo of the Carlyle Group is displayed at the company's office in Tokyo, Japan October 17, 2018. REUTERS/Issei Kato/File Photo
BAX
-
CG
-

(Reuters) -Private equity firm Carlyle Group (NASDAQ:CG) is in exclusive talks to acquire Baxter International (NYSE:BAX)'s kidney care spinoff Vantive for more than $4 billion, including debt, a person familiar with the matter told Reuters on Friday.

Shares of the Deerfield, Illinois-based firm rose more than 4%.

The parties had entered exclusive negotiations in late June, the person said, adding that a deal could be announced in the coming weeks.

Medical device maker Baxter said in March it had been in discussions with select private equity investors to explore a potential sale of the kidney care unit more than a year after it announced plans to separate the unit amid supply-chain challenges and weak demand for dialysis operations.

Baxter had said it plans to separate the unit in the second half of the year.

© Reuters. FILE PHOTO: The logo of the Carlyle Group is displayed at the company's office in Tokyo, Japan October 17, 2018. REUTERS/Issei Kato/File Photo

Baxter declined to comment while Carlyle did not immediately respond to a Reuters request for comment.

The Wall Street Journal first reported on the matter.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.